Popular Ice Cream Brand Recalled Across 23 States for This Dangerous Reason—Here's What to Know
There's nothing better than a sweet treat like ice cream on a hot summer day. It's cool and refreshing, sweet and creamy, and all around everything right in the world. You can enjoy it in your favorite flavors, whether you prefer more classic fare like cookies and cream or something a bit more out there like mustard or blueberry goat cheese with basil pesto swirl. Ice cream is quintessential summer, and despite the fact that we enjoy it year-round, it tastes so much better in the sunshine.
😋😋SIGN UP to get delicious recipes, handy kitchen hacks & more in our daily Pop Kitchen newsletter🍳🍔
As sweet and unassuming as ice cream can be, though, sometimes it isn't the safe, innocuous treat that we've come to know and love. Beyond the fact that it can be a sugar and cholesterol bomb, if it isn't made right, it can actually be dangerous. Ice cream can be a breeding ground for bacteria due to fluctuations in temperature during processing and improper cleaning of equipment, and you might not know until it's too late. Luckily, there are safeguards in place to catch any potential issues before our favorite summer treat makes it to our freezers—but that doesn't mean that accidents don't happen.Unfortunately, you might want to double-check your freezer to make sure you don't have one of the slew of items affected by a recent recall affecting ice cream bars sold in a whopping 23 states. According to recent filings by the FDA, over 100,000 ice cream bars produced by Rich's Ice Cream were recalled due to concerns over potential listeria contamination. The recall, which impacts lot number 24351 through lot 25156, was initiated on June 27, according to the FDA notice, and is classified as Class II with a total of 110,292 cases potentially affected.
The impacted products include Chocolate Crunch Cake Bars, Strawberry Shortcake Bars, Rich Bars, Crumbled Cookie Bars, Orange Cream Bars, Fudge Frenzy Bars, Cotton Candy Twirl Bars, Savagely Sour Blue Raspberry Bars, Savagely Sour Cherry Bars, and Cool Watermelon Bars. Additionally, the frozen treats were individually packaged in plastic bags and sold in master cases.
As if the list of items weren't exhaustive enough, the potentially contaminated products were sold in Alabama, Arizona, California, South Carolina, Florida, Georgia, Illinois, Iowa, Louisiana, Massachusetts, Missouri, Nebraska, Nevada, New Jersey, New York, Ohio, Oklahoma, Oregon, Pennsylvania, Tennessee, Texas, Virginia, and Wisconsin. They were also distributed and sold in Nassau, Bahamas. Talk about ruining your summer vacation.
So far, there don't appear to be any reported illnesses, but it's worth it to tread with caution if you think you might have purchased the affected products. To find out more information or contact Rich's Ice Cream Co., you can visit their website, and be sure to check back here for the latest food news.Popular Ice Cream Brand Recalled Across 23 States for This Dangerous Reason—Here's What to Know first appeared on Parade on Jul 22, 2025
This story was originally reported by Parade on Jul 22, 2025, where it first appeared.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
4 minutes ago
- Associated Press
Scientist.com Expands Tumor Model Finder with XenoSTART's Highly Relevant, Patient-Derived Tumor Models
SAN DIEGO--(BUSINESS WIRE)--Jul 23, 2025-- the leading R&D procurement orchestration platform for the life sciences, today announced a major expansion of its Tumor Model Finder (TMF) following a strategic partnership with XenoSTART, a global leader in patient-derived xenograft (PDX) model development and testing. The addition of hundreds of unique and high-demand XenoSTART models pushes the TMF past a milestone of 10,000 searchable oncology models, giving cancer researchers unprecedented access to diverse and clinically relevant tools. 'Pharma discovery teams often face critical delays accessing translational research partners with deeply characterized PDX models that accurately reflect real-world patient disease complexity,' said Michael J. Wick, PhD, Chief Scientific Officer at XenoSTART. 'By joining the marketplace, XenoSTART eliminates this significant barrier, providing immediate access to our highly relevant, patient-derived tumor models that are directly linked to our global clinical network. This integration empowers drug developers to confidently accelerate therapeutic decision-making and precisely guide their translational strategies—ultimately speeding effective cancer treatments to patients.' Tumor Model Finder is a centralized, AI-powered platform that aggregates and standardizes tumor model data from 20+ leading CROs. It allows researchers to search, compare, and source PDX, CDX, organoid, and cell line models—spanning 17 cancer types—through a single workflow. The platform also includes drug response profiles, genomic alterations (e.g., KRAS, BRAF mutations), and RNA seq-based gene expression data to support informed model selection and study design. 'XenoSTART's contribution significantly boosts the depth and quality of our TMF offerings,' said Javier Pineda, PhD, Director of Preclinical AI at 'Researchers can now find models with richer data and greater relevance to their specific cancer studies.' This collaboration also highlights the translational impact of START's global research ecosystem. With patient-derived tissue samples sourced from START's expansive oncology trial network, XenoSTART's models provide critical continuity between preclinical evaluation and clinical trial execution—helping pharmaceutical companies make faster, more confident decisions in oncology drug development. To learn more or schedule a demo of the Tumor Model Finder, email [email protected]. About is the life-science industry's premier AI-powered marketplace and procurement-orchestration platform. Founded in 2007 and headquartered in Solana Beach, California, the company simplifies every stage of drug discovery and development by unifying supplier search, competitive bidding, contracting, compliance and analytics in a single, secure workspace. More than 20 of the world's top 30 pharma companies, 100+ biotech organizations and the US National Institutes of Health rely on to access a vetted network of 6,000+ specialized providers, shorten cycle times and reduce costs while meeting the highest ethical and regulatory standards. Visit to discover how we accelerate science. About XenoSTART Founded in 2007, XenoSTART is a translational research organization dedicated to advancing oncology drug development through clinically relevant preclinical cancer models. The XenoSTART Patient-Derived Xenograft (XPDX) platform features more than 2,800 models across a broad range of tumor types and disease stages sourced from patients treated at START's domestic and international cancer centers. Models are deeply characterized using histologic analysis, DNA/RNA sequencing, and in vivo drug sensitivity testing, and are clinically annotated with the donor patient's treatment history and clinical outcome. By bridging real-world tumor biology with rigorous preclinical science, XenoSTART enables pharmaceutical partners to make smarter, faster decisions from bench to bedside. Learn more about XenoSTART at View source version on CONTACT: Sean Preci +1 877-644-3044 [email protected] XenoSTART Lauren Panco 609-216-4920 KEYWORD: EUROPE UNITED STATES NORTH AMERICA CALIFORNIA INDUSTRY KEYWORD: OTHER HEALTH RESEARCH PHARMACEUTICAL ONCOLOGY TECHNOLOGY ARTIFICIAL INTELLIGENCE GENETICS HEALTH TECHNOLOGY SCIENCE BIOTECHNOLOGY OTHER SCIENCE HEALTH SOURCE: Copyright Business Wire 2025. PUB: 07/23/2025 07:55 AM/DISC: 07/23/2025 07:55 AM
Associated Press
5 minutes ago
- Associated Press
Avel eCare Appoints Martainn Lenhardt as Chief Financial Officer to Lead Financial Strategy Amid Rapid Growth and Innovation
SIOUX FALLS, SD / ACCESS Newswire / July 23, 2025 / Avel eCare, a leading provider of telemedicine services in the United States, today announced the appointment of Martainn Lenhardt as Chief Financial Officer (CFO). Lenhardt brings over 20 years of healthcare finance experience to the role, where he will oversee Avel's financial strategy, operations, and performance during a pivotal era of innovation and nationwide expansion. Lenhardt joins Avel eCare following his tenure as VP of Finance at Lyric and senior leadership roles at Change Healthcare, where he managed a $480 million business unit and was instrumental in driving growth and improving margins. He is widely recognized for his expertise in strategic growth, mergers and acquisitions, and optimizing global operations. His ability to turn complexity into opportunity and build agile, purpose-driven teams will be instrumental in advancing Avel's mission. 'Avel eCare is transforming how healthcare is delivered across the country,' said Lenhardt. 'It's an honor to join this team and help scale a model that brings high-quality, virtual care to every corner of the nation.' This appointment comes at a time of unprecedented momentum for Avel eCare. In the past two years alone, Avel has launched new service lines, secured exclusive partnerships with organizations like Amwell and Cibolo Health, and expanded services to more than 46 states. The company continues to innovate with in-ambulance telehealth, ICU solutions, and programs that support EMS, law enforcement, and correctional health, making care more accessible, cost-effective, and consistent, especially in rural and underserved areas. The new CFO joins an accomplished executive team committed to advancing healthcare access and outcomes across the country. Avel's leadership includes: About Avel eCare Avel eCare is a national leader in technology-enabled clinical services delivered through telemedicine, offering provider-to-provider virtual care solutions that expand clinical capacity and improve outcomes across the healthcare industry. With more than 30 years of innovation, Avel's board-certified clinicians partner with hospitals, clinics, long-term care facilities, schools, EMS agencies, and correctional health systems nationwide to bring high-quality care to patients when and where it's needed most. Learn more at: Media Contact: Jessica Gaikowski Avel eCare [email protected] SOURCE: Avel eCare press release
Washington Post
5 minutes ago
- Washington Post
The world should strive to end PEPFAR
Last week, the President's Emergency Plan for AIDS Relief narrowly escaped a devastating $400 million budget cut thanks to Republican Sens. Susan Collins (Maine) and Lisa Murkowski (Alaska), who voted alongside their Democratic colleagues to protect the program. That was a relief: Since its creation under President George W. Bush in 2003, the anti-HIV/AIDS program has saved an estimated 26 million lives and enabled 7.8 million babies to be born HIV-free.
